Nextcure announces three new members of its scientific advisory board

Beltsville, md., oct. 19, 2021 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointments of elizabeth jaffee, m.d., ursula matulonis, m.d., and weiping zou, m.d., ph.d., to its scientific advisory board (sab). ethan shevach, m.d., will retire from the sab. drs. lieping chen, m.d., ph.d., mario sznol, m.d., and stephen miller, ph.d., will continue to serve on the sab.
NXTC Ratings Summary
NXTC Quant Ranking